Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
AstraZeneca
AstraZeneca
Merck Sharp & Dohme LLC
BriaCell Therapeutics Corporation
AstraZeneca
Hoffmann-La Roche
Artiva Biotherapeutics, Inc.
Merck Sharp & Dohme LLC
BriaCell Therapeutics Corporation
GC Cell Corporation
Bristol-Myers Squibb
Acepodia Biotech, Inc.
Prestige Biopharma Limited
Hoffmann-La Roche
Spectrum Pharmaceuticals, Inc
AryoGen Pharmed Co.
Hoffmann-La Roche
RemeGen Co., Ltd.
Samyang Biopharmaceuticals Corporation
Palleos Healthcare GmbH
RemeGen Co., Ltd.
Genexine, Inc.
Teva Branded Pharmaceutical Products R&D, Inc.
Leap Therapeutics, Inc.
Fate Therapeutics
Fate Therapeutics
Aileron Therapeutics, Inc.
Hoffmann-La Roche
Hoffmann-La Roche
Spectrum Pharmaceuticals, Inc
Spectrum Pharmaceuticals, Inc
Tanvex BioPharma USA, Inc.
Marker Therapeutics, Inc.
GlaxoSmithKline
BriaCell Therapeutics Corporation
Prescient Therapeutics, Ltd.
Hoffmann-La Roche
Celgene
Hoffmann-La Roche
AstraZeneca
Hoffmann-La Roche
Eske Corporation S.A.C
Hoffmann-La Roche
Merck Sharp & Dohme LLC
GlaxoSmithKline
Merrimack Pharmaceuticals
Sanofi
Hoffmann-La Roche
GlaxoSmithKline
Bristol-Myers Squibb
Merck Sharp & Dohme LLC